Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

Development of T cell-directed immune checkpoint inhibitors (ICI) has revolutionized metastatic melanoma (MM) therapy, but <50% of treated patients experience durable responses. This phase I trial (NCT01946373) investigates the safety/feasibility of tumor-infiltrating lymphocyte (TIL) adoptive ce...

Full description

Bibliographic Details
Main Authors: Tanja Lövgren, Maria Wolodarski, Stina Wickström, Ulrika Edbäck, Mette Wallin, Eva Martell, Katrin Markland, Pontus Blomberg, Maria Nyström, Andreas Lundqvist, Hans Jacobsson, Gustav Ullenhag, Per Ljungman, Johan Hansson, Giuseppe Masucci, Roger Tell, Isabel Poschke, Lars Adamson, Jonas Mattsson, Rolf Kiessling
Format: Article
Language:English
Published: Taylor & Francis Group 2020-01-01
Series:OncoImmunology
Subjects:
combination immunotherapy
adoptive tumor-infiltrating lymphocyte therapy
tumor lysate
dc vaccination
immune checkpoint inhibitor resistance
Online Access:http://dx.doi.org/10.1080/2162402X.2020.1792058

Internet

http://dx.doi.org/10.1080/2162402X.2020.1792058

Similar Items